EEB: KRAS: Clinical Implications
Craig Mackinnon, MD, PhD
The University of Alabama at Birmingham
Kurtis Davies, PhD
This microlearning module discusses the clinical implications of the recent and relevant research on the biomarker KRAS. It is part of the Emerging and Evolving Biomarkers: KRAS: Recent Findings, Laboratory Considerations, and Clinical Implications webinar.
This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.